NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma-Reference-Cited by-同舟云学术

NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma

Published:2017-10-17 Issue:3 Volume:124 Page:537-545
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

McWilliams Robert R.¹^ORCID,Allred Jacob B.²,Slostad Jessica A.³,Katipamula Rajini⁴,Dronca Roxana S.¹,Rumilla Kandelaria M.⁵,Erickson Lori A.⁶^ORCID,Bryce Alan H.⁷,Joseph Richard W.⁸,Kottschade Lisa A.¹,King David M.⁹,Leitch John M.¹⁰,Markovic Svetomir N.¹

Affiliation:

1. Division of Medical Oncology; Mayo Clinic; Rochester Minnesota

2. Alliance Statistics and Data Center; Mayo Clinic; Rochester Minnesota

3. Department of Medicine; Mayo Clinic; Rochester Minnesota

4. Minnesota Oncology; Coon Rapids; Minnesota

5. Division of Molecular Genetics; Mayo Clinic; Rochester Minnesota

6. Division of Anatomic Pathology; Mayo Clinic; Rochester Minnesota

7. Division of Hematology/Oncology, Mayo Clinic in Arizona; Scottsdale Arizona

8. Division of Hematology/Oncology, Mayo Clinic in Florida; Jacksonville Florida

9. Unity Hospital, Metro Minnesota Community Oncology Research Consortium; Saint Louis Park Minnesota

10. Sanford Clinic North-Fargo; Fargo North Dakota

Funder